JPRN-UMIN000032865已完成未知
A randomized controlled trial comparing capecitabine 5-days-on/2-days-off regimen with conventional regimen in stage II and III colorectal cancer. - A randomized clinical trial of capecitabine 5-days-on/2-days-off regimen or conventional regimen in colorectal cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. duplicated active cancer 2. history of severe drug hypersensitivity 3. clinically problematic infection 4. it is judged that registration in this study is difficult due to clinically problematic mental / neurological diseases 5. any of the following complications i) diabetes with poor control ii) hypertension with poor control iii) interstitial pneumonia or pulmonary fibrosis iv) intestinal palsy or intestinal obstruction v) clinically problematic heart disease 6. already undergoing other chemotherapy before and after surgery 7. temporary ileostomy/colostomy closure is scheduled and the administration period of continuous 24 weeks is interrupted for a long time (8) Other cases that the doctor in charge judged unsuitable for safely carrying out this study.
研究者
相似试验
进行中（未招募）
不适用
Tesetaxel, an oral taxane, and capecitabine versus placebo and capecitabine in gastric cancerHistologically or cytologically confirmed gastric carcinoma, including gastric or gastroesophageal-junction adenocarcinomaMedDRA version: 14.1Level: LLTClassification code 10017760Term: Gastric cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022164-12-DEGenta Incorporated580
已完成
不适用
Randomised phase II study comparing capecitabine with oral cyclophosphamide and capecitabine in patients with advanced breast cancerAdvanced breast cancerCancerBreast cancerISRCTN68662102Cancer Trials New Zealand (CTNZ) (New Zealand)82
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern
尚未招募
2 期
Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients.metastatic breast carcinomaJPRN-UMIN000013045Japan Breast Cancer Research Network60
已完成
2 期
Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer PatientsInoperable or recurrent breast cancerJPRN-UMIN000000609Japan Breast Cancer Research Network130